madman
Super Moderator
Bad science and sensationalized headlines continue to create unnecessary fear surrounding hormone therapy, often overshadowing the clinical benefits for postmenopausal women. Rachel Rubin, MD, and Kelly Casperson, MD, discuss the critical need for medical professionals to look beyond "clickbait" study results and understand the nuances of hormone delivery methods and patient-specific goals.
This discussion highlights the recent FDA removal of certain box warnings on vaginal hormone products and addresses the persistent gaps in menopause education for primary care providers. By examining the flaws in recent retrospective studies, Rachel Rubin, MD, and Kelly Casperson, MD, emphasize that stopping hormone therapy can carry its own significant risks, including increased bone loss and urological complications. This content serves as a guide for clinicians to employ shared decision-making, utilizing logic and updated data rather than historical fears to provide optimal care for the aging female population.
Chapters
00:00 - Introduction to Sex Matters
00:15 - FDA Labeling Changes for Hormone Therapy
01:30 - The Education Gap in Menopause Medicine
02:10 - Analyzing Flawed Research and Misleading Headlines
03:45 - Understanding Different Hormone Delivery Methods
05:15 - Correlation vs. Causation in Clinical Studies
06:25 - Individualized Risk-Benefit Assessments
07:15 - Long-term Benefits of Estrogen Therapy
08:45 - Moving Beyond Fear-Based Clinical Decisions
